Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to see if psilocybin, an investigational drug, is safe and well tolerated. Researchers also want to know if psilocybin can improve symptoms of depression. This study will see if psilocybin is safe and well tolerated by tracking changes in suicidal thoughts and behaviour, monitoring if any participants choose to stop participating in the study, and measuring any serious side effects, as well as how long they take to resolve. This study will also see if depression symptoms improve (or worsen) after psilocybin is administered. Additional information about participants' depressive symptoms and side effects will also be measured during the study.


Clinical Trial Description

This randomized clinical trial will assess the feasibility, safety, and efficacy of single and repeat doses of psilocybin at point-of-care in persons with treatment-resistant depression as part of major depressive disorder or bipolar II disorder. The primary objective is to evaluate the feasibility of psilocybin in adults with treatment-resistant depression. The secondary objectives are to assess the efficacy and tolerability of psilocybin at point-of-care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05029466
Study type Interventional
Source Brain and Cognition Discovery Foundation
Contact Joshua D Rosenblat, MD, MSc
Phone (416) 430-9619
Email [email protected]
Status Not yet recruiting
Phase Phase 2
Start date October 2021
Completion date December 2022

See also
  Status Clinical Trial Phase
Recruiting NCT03887715 - A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression N/A
Enrolling by invitation NCT04634669 - Open-Label Safety Study of AXS-05 in Subjects With TRD Phase 2
Withdrawn NCT03175887 - Investigational TMS Treatment for Depression N/A
Completed NCT03134066 - Neurocognitive Features of Patients With Treatment-Resistant Depression
Active, not recruiting NCT01984710 - DBS for TRD Medtronic Activa PC+S N/A
Completed NCT01935115 - Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy Phase 4
Terminated NCT01687478 - A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression Phase 3
Completed NCT00531726 - Berlin Deep Brain Stimulation Depression Study N/A
Recruiting NCT04739865 - The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression Phase 2
Not yet recruiting NCT04124341 - EpCS in Severe Treatment Resistant Depression N/A
Not yet recruiting NCT04099342 - Enhanced Spatial Targeting in ECT Utilizing FEAST N/A
Recruiting NCT04959253 - Psilocybin in Depression Resistant to Standard Treatments Phase 2
Completed NCT04856124 - Intranasal Esketamine to Maintain the Antidepressant Response to IV Racemic Ketamine
Recruiting NCT03272698 - ECT With Ketamine Anesthesia vs High Intensity Ketamine With ECT Rescue for Treatment-Resistant Depression Phase 4
Recruiting NCT04451135 - CET- REM (Correlating ECT Response to EEG Markers) N/A
Recruiting NCT03288675 - Stepped Care aiTBS 2 Depression Study (Ghent) N/A
Terminated NCT02675556 - Allogeneic Human Mesenchymal Stem Cells (hMSCs) Infusion in Patients With Treatment Resistant Depression Phase 1
Recruiting NCT04504175 - Ketamine for Older Adults Pilot Phase 4
Recruiting NCT03711019 - Efficacy of Convulsive Therapies During Continuation N/A
Recruiting NCT03428828 - Neurofeedback for Treatment Resistant Depression N/A